Devin Lowe

Devin Lowe, Ph.D., is a tenured Associate Professor in the Department of Immunotherapeutics and Biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy. Based at the Abilene campus (1718 Pine Street), he leads an active research laboratory focused on tumor immunology and angiogenesis. His work bridges basic science on tumor microenvironment mechanisms and translational development of cancer immunotherapies.

Education includes:

• Postdoctoral Fellowship: American Cancer Society Fellowship, University of Pittsburgh School of Medicine (2013)
• Ph.D.: Texas Tech University Health Sciences Center (2010)

Dr. Lowe's research investigates tumor blood vessel destruction via immune interventions and the interplay between immune cells, vasculature, and cancer. Key focus areas include:

• Mechanistic studies of vascular disruption during immunotherapy
• Development of anti-angiogenesis immunotherapies for vascularized cancers
• Design of diagnostic assays for treatment personalization

His work addresses tumor microenvironment challenges like hypoxia, immune evasion, and immunosuppressive cell networks.

Recent publications (2012-2022) demonstrate consistent focus on dendritic cell vaccines, antibody-drug conjugates, and combination therapies targeting tumor vasculature. Research utilizes both preclinical models and clinical data, emphasizing melanoma and colorectal cancer. Recurring themes include overcoming immune checkpoint resistance, enhancing T-cell responses, and vascular-targeting strategies.

Scientific recognition includes:

• American Cancer Society Fellowship

Research is supported by major grants:

• NIH R15 CA215874
• DOD W81XWH-18-1-0293
• Dodge Jones Foundation

Dr. Lowe holds a patent for tumor-associated stromal antigen peptides (US #9,345,770).

The Lowe Lab (Room 1315) conducts experimental work on tumor immunology and angiogenesis. Teams investigate basic mechanisms of vascular-immune interactions while developing clinical translation strategies, including diagnostic tools for patient-specific therapeutic design.